Fate Therapeutics, Inc.
NASDAQ:FATEBiotechnology
-$0.00 today
- Market cap
- $118.89M
- Beta
- 2.52
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.08
Volume 2.43M
Average 2.92M
FATE EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Fate Therapeutics, Inc.NASDAQ: FATE
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$28.3M, compared with -$34.29M a year earlier. Trailing-twelve-month EBITDA was -$117.42M.
Context
- EBITDA amounted to 1911.2% of revenue in FY2025, up 615.8 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$110.93M (+12.7%) for the fiscal year ending Dec 2026, a slowdown from the +28.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$28.3M+3.5% QoQ
- Last fiscal yearDec 2025
- -$127.02M+28.1% YoY
- LTMMar 2026
- -$117.42M+23.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +17.5% | +1.7% | -15.8 pp |
| 1 year | +28.1% | +12.7% | -15.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (127.02M) USD
- Year-over-year change
- +28.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (127.02M) | +28.1% |
| FY2024 | 2024-12-31 | (176.58M) | -23.8% |
| FY2023 | 2023-12-31 | (142.65M) | +46.8% |
| FY2022 | 2022-12-31 | (267.96M) | -29.9% |
| FY2021 | 2021-12-31 | (206.3M) | — |
EBITDA vs competitors
How FATE compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +23.4% is the 3rd highest of 10, against a peer median of +10.7%.
- EBITDA amounts to 1859.1% of revenue for FATE, versus a peer median of 543.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $449.13M USD | +489.9% | — | — | |
| LTM Mar 2026 | -CHF 63.08M CHF | -8.3% | — | — | |
| LTM Mar 2026 | -$75.99M USD | +22.0% | — | — | |
| LTM Mar 2026 | -$76.13M USD | +39.6% | — | 455.3% | |
| LTM Mar 2026 | -$81.94M USD | +12.2% | — | — | |
| LTM Mar 2026 | -$84.28M USD | -67.4% | — | — | |
| LTM Mar 2026 | -$90.7M USD | +10.7% | — | — | |
| LTM Mar 2026 | -$108.82M USD | +2.8% | — | — | |
| LTM Mar 2026 | -$116.42M USD | -1.3% | — | 632.1% | |
| LTM Mar 2026 | -$117.42M USD | +23.4% | — | 1859.1% | |
| Peer median (excluding FATE) | — | +10.7% | — | 543.7% | |
Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.85M | 96.3M | 63.53M | 13.63M | 6.65M |
| Cost of Revenue | 5.85M | 13.76M | 157.19M | 118.53M | 12.9M |
| Gross Profit | 50M | 82.54M | (93.65M) | (104.9M) | (6.26M) |
| Gross Margin | 89.5% | 85.7% | -147.4% | -769.6% | -94.1% |
| Research & Development | 215.52M | 320.45M | 172.6M | 135M | 107.83M |
| Selling, General & Admin | 57.32M | 84.23M | 96.86M | 90.64M | 46.52M |
| Operating Expenses | 266.99M | 390.93M | 96.86M | 105.38M | 141.45M |
| Depreciation & Amortization | 5.85M | 13.76M | 18.28M | 18.96M | 9.3M |
| EBITDA | (206.3M) | (267.96M) | (142.65M) | (176.58M) | (127.02M) |
| EBITDA Margin | -369.4% | -278.3% | -224.5% | -1295.4% | -1911.2% |
| Operating Income | (216.99M) | (308.39M) | (190.51M) | (210.28M) | (147.7M) |
| Operating Margin | -388.6% | -320.2% | -299.9% | -1542.6% | -2222.4% |
| Interest Income | 1.31M | 5.84M | 17.19M | 17.29M | 11.05M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.84M | 26.67M | 29.58M | 24.01M | 11.39M |
| Income Before Tax | (212.15M) | (281.72M) | (160.93M) | (186.26M) | (136.32M) |
| Pre-Tax Margin | -379.9% | -292.5% | -253.3% | -1366.5% | -2051.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (212.15M) | (281.72M) | (160.93M) | (186.26M) | (136.32M) |
| Net Margin | -379.9% | -292.5% | -253.3% | -1366.5% | -2051.1% |
| EPS (Basic) | (2.24) | (2.91) | (1.64) | (1.64) | (1.15) |
| EPS (Diluted) | (2.24) | (2.91) | (1.64) | (1.64) | (1.15) |
| Weighted Avg Shares | 94.75M | 96.83M | 98.41M | 113.69M | 118.79M |
| Weighted Avg Shares (Diluted) | 94.75M | 96.83M | 98.41M | 113.69M | 118.79M |
Fate Therapeutics, Inc.
NASDAQ:FATE
Intrinsic Alpha fair value
Locked
Current Price
$1.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.